Cargando…

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells

In the treatment of metastatic melanoma, a highly therapy-refractory cancer, alkylating agents are used and, for the subgroup of BRAF(V600E) cancers, the B-Raf inhibitor vemurafenib. Although vemurafenib is initially beneficial, development of drug resistance occurs leading to tumor relapse, which n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roos, Wynand P., Quiros, Steve, Krumm, Andrea, Merz, Stephanie, Switzeny, Olivier Jérôme, Christmann, Markus, Loquai, Carmen, Kaina, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350346/ https://www.ncbi.nlm.nih.gov/pubmed/25557167

Ejemplares similares

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Survival and Death Strategies in Glioma Cells: Autophagy, Senescence and Apoptosis Triggered by a Single Type of Temozolomide-Induced DNA Damage
por: Knizhnik, Anna V., et al.
Publicado: (2013)

Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs
por: Quiros, Steve, et al.
Publicado: (2011)

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics
por: Beltzig, Lea, et al.
Publicado: (2022)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
por: Switzeny, Olivier J., et al.
Publicado: (2016)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study
por: Guida, Michele, et al.
Publicado: (2010)

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome
por: Reich, Thomas R., et al.
Publicado: (2017)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial
por: Marinelli, Alfredo, et al.
Publicado: (2018)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

Temozolomide – Just a Radiosensitizer?
por: Kaina, Bernd, et al.
Publicado: (2022)

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells
por: Beltzig, Lea, et al.
Publicado: (2022)

Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69
por: Kaina, Bernd
Publicado: (2019)

Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts
por: Acciardo, Stefania, et al.
Publicado: (2019)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
por: He, Yang, et al.
Publicado: (2019)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation
por: Ristić-Fira, Aleksandra M, et al.
Publicado: (2009)

Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment
por: Schwarzenbach, Christian, et al.
Publicado: (2021)

Long-lasting tumor response on short-time administration of vemurafenib—A case report
por: Mitzel, Heidrun, et al.
Publicado: (2014)

Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM
por: Tomicic, Maja T., et al.
Publicado: (2015)

CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways
por: Al Shahrani, Mesfer, et al.
Publicado: (2022)

The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair
por: Roos, Wynand Paul, et al.
Publicado: (2016)

Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression
por: Hanisch, Daniela, et al.
Publicado: (2022)

Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation
por: Christmann, Markus, et al.
Publicado: (2013)

Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells
por: Kaina, Bernd, et al.
Publicado: (2020)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis
por: Genovese, Tiziana, et al.
Publicado: (2021)

Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair
por: Christmann, Markus, et al.
Publicado: (2016)

Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib
por: Telang, Sucheta, et al.
Publicado: (2014)

Death of Monocytes through Oxidative Burst of Macrophages and Neutrophils: Killing in Trans
por: Ponath, Viviane, et al.
Publicado: (2017)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tdm5roo91vfldjr4ff2vq8blnf